Bruker (BRKR) Expected to Announce Quarterly Earnings on Wednesday

Bruker (NASDAQ:BRKR - Get Free Report) is expected to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Bruker to post earnings of $0.26 per share and revenue of $794.8090 million for the quarter. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The company had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. During the same period in the prior year, the business earned $0.76 earnings per share. Bruker's revenue for the quarter was down .2% compared to the same quarter last year. On average, analysts expect Bruker to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bruker Price Performance

Bruker stock opened at $36.26 on Wednesday. Bruker has a one year low of $28.53 and a one year high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The business has a fifty day moving average of $37.28 and a two-hundred day moving average of $41.99. The company has a market cap of $5.52 billion, a P/E ratio of -241.73, a price-to-earnings-growth ratio of 2.19 and a beta of 1.20.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a yield of 0.6%. Bruker's dividend payout ratio (DPR) is -133.33%.

Analysts Set New Price Targets

A number of research firms have commented on BRKR. TD Cowen raised Bruker to a "hold" rating in a report on Monday, April 13th. Jefferies Financial Group set a $50.00 target price on Bruker in a report on Thursday, February 12th. Weiss Ratings raised Bruker from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday. Citigroup reduced their target price on Bruker from $53.00 to $40.00 and set a "neutral" rating for the company in a report on Friday, February 13th. Finally, Barclays cut their price target on Bruker from $50.00 to $45.00 and set an "overweight" rating for the company in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $49.38.

Insider Activity

In other news, VP Mark Munch sold 2,000 shares of Bruker stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president owned 128,443 shares of the company's stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 27.20% of the stock is owned by company insiders.

Institutional Trading of Bruker

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC purchased a new stake in Bruker during the 2nd quarter worth about $297,000. Banco Bilbao Vizcaya Argentaria S.A. purchased a new stake in Bruker during the 4th quarter worth about $224,000. iSAM Funds UK Ltd purchased a new stake in Bruker during the 2nd quarter worth about $217,000. CIBC Asset Management Inc purchased a new stake in Bruker during the 4th quarter worth about $203,000. Finally, Twin Tree Management LP increased its position in Bruker by 195.0% during the 3rd quarter. Twin Tree Management LP now owns 5,616 shares of the medical research company's stock worth $182,000 after purchasing an additional 11,528 shares in the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker's product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.